Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
about
Reviewing the diagnostic criteria for acute-on-chronic liver failure.The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray.The soluble mannose receptor is released from the liver in cirrhotic patients, but is not associated with bacterial translocation.Low serum transferrin correlates with acute-on-chronic organ failure and indicates short-term mortality in decompensated cirrhosis.Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes.The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients.Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.Single-centre experience of the macrophage activation marker soluble (s)CD163 - associations with disease activity and treatment response in patients with autoimmune hepatitis.Editorial: measuring inflammatory and fibrotic components of portal hypertension - a non-invasive hepatic venous pressure gradient? Authors' reply.The macrophage activation marker sCD163 combined with markers of the Enhanced Liver Fibrosis (ELF) score predicts clinically significant portal hypertension in patients with cirrhosis.The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.Immunodysfunction in Acute-on-Chronic Liver FailureHigh hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional studyNo effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial
P2860
Q30243874-26C80D13-924E-43CF-B915-719AC584151AQ38999160-4D03202B-34E3-4DFD-84BA-1EFDA53DA610Q40495697-21E281AC-E128-46EF-825E-052099C49BD3Q40595042-87E55673-432C-45BE-9F66-FD6BEF00FC75Q41786318-A9315651-D293-423C-9E0D-D7EB34AF587AQ47132141-2119E394-9A85-4544-A885-6D8B4033788AQ47266129-523D1C0B-7DAF-4B5F-B486-1C4EE30B60A4Q47993022-329E0F75-2847-4C07-B1A2-C57CAA49636DQ50237588-A14644B9-ADF4-4F47-85DD-E7A0C7258A34Q50245155-9AC7687B-B796-4BF7-BA03-493CA8BE5E52Q52873745-9662E741-E60F-466D-8B53-6016BCB351CEQ57824681-2548AC5F-F602-4174-B727-96A60E343A2DQ58706878-75B659E7-F7C1-4203-9925-E8DD86C740F8Q58763693-2EEFBD36-F3ED-44BA-8646-AB26E2B1411F
P2860
Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Macrophage activation markers ...... -chronic liver failure (ACLF).
@en
type
label
Macrophage activation markers ...... -chronic liver failure (ACLF).
@en
prefLabel
Macrophage activation markers ...... -chronic liver failure (ACLF).
@en
P2093
P50
P1476
Macrophage activation markers ...... n-chronic liver failure (ACLF)
@en
P2093
CANONIC study investigators of the EASL-CLIF Consortium
Elisabet Garcia
Hendrik Vilstrup
Marco Domenicali
Niels Kristian Aagaard
Sidsel Rødgaard-Hansen
P304
P356
10.1016/J.JHEP.2015.11.021
P577
2015-11-27T00:00:00Z